Abstract | OBJECTIVE: CASE SUMMARY: DISCUSSION: The emergence of VRE infections presents a treatment challenge in immunocompromised patients. When treating VRE infections in this patient population, the effectiveness of linezolid and quinupristin/dalfopristin is limited by their bacteriostatic activity when used as monotherapy. Recent in vitro data suggest synergistic activity with quinupristin/dalfopristin when used in combination with other antimicrobials in selected isolates of VRE. CONCLUSIONS:
|
Authors | J Audis Bethea, Christine M Walko, Patricia A Targos |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 38
Issue 6
Pg. 989-91
(Jun 2004)
ISSN: 1060-0280 [Print] United States |
PMID | 15100393
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Anti-Bacterial Agents
- Virginiamycin
- quinupristin-dalfopristin
- Ampicillin
|
Topics |
- Adult
- Ampicillin
(administration & dosage, therapeutic use)
- Anti-Bacterial Agents
(administration & dosage, therapeutic use)
- Bacteremia
(complications, drug therapy, microbiology)
- Drug Therapy, Combination
- Enterococcus faecium
- Female
- Humans
- Leukemia, Myeloid, Acute
(complications, drug therapy)
- Neutropenia
(complications)
- Staphylococcal Infections
(complications, drug therapy)
- Vancomycin Resistance
- Virginiamycin
(administration & dosage, therapeutic use)
|